XNAS · Healthcare · Biotechnology
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Micro-cap biotech delivered massive **$1.04 EPS beat** vs estimates, with revenue surging 39% above expectations to $477K. Exceptional earnings quality suggests potential pipeline progress.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | Q1 2026 | -1.04 | 0.00 | +100.00% | $477,000 | ✅ Beat | +2.85% | -2.67% | — |
| 2026-03-23 | Q4 2025 | -0.54 | -0.34 | +37.04% | $194,000 | ✅ Beat | +3.77% | -3.02% | -3.45% |
| 2025-11-24 |
| Q3 2025 |
| -0.49 |
| -0.22 |
| +55.10% |
| $427,000 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-31 | Q4 2024 | 0.00 | 0.00 | — | $11.7M | ➖ Inline | -1.35% | -14.86% | +17.23% |
| 2024-11-25 | Q3 2024 | -0.10 | -0.07 | +30.00% | $4.9M | ✅ Beat | +1.66% | +7.25% | -17.52% |
| 2024-08-15 | Q2 2024 | -0.14 | 0.00 | +100.00% | $5.4M | ✅ Beat | +8.88% | +6.15% | -5.65% |
| 2024-05-28 | Q1 2024 | -0.29 | -0.01 | +96.55% | $6.9M | ✅ Beat | -4.03% | -2.81% | -20.72% |
| 2024-03-26 | Q4 2023 | -0.22 | -0.15 | — | $4.8M | ✅ Beat | — | — | — |
Showing last 8 quarters.